IONS vs MRK
Ionis Pharmaceuticals, Inc. vs Merck & Co. — AI-powered side-by-side comparison
IONS
Ionis Pharmaceuticals, Inc.
43
Reduce
VS
| Metric | IONS | MRK |
|---|
| AI Score |
43
|
70
|
| Price |
$55.38
|
$130.34
|
| P/E Ratio |
-16.02×
|
103.53×
|
| ROE |
-77.9%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
98.2%
|
75.4%
|
| Debt / Equity |
5.50×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
46.6
|
64.5
|
| Beta |
0.4
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for IONS versus MRK.
MRK leads by 27 points.
MRK scores 70/100 (Buy) versus IONS at 43/100 (Reduce).
IONS Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 26.2x prices in significant intangible value — Value
- ROE of only -110.9% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical